Study Details

A Study of an Intratumoral Oncolytic Virus in Patients with Advanced Metastatic Solid Tumors

Recruitment complete
The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled. ID

The unique identification code given to each clinical study upon registration at

Astellas Study ID

The unique identification code given by the study sponsor.


EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).



Advanced/Metastatic Cancer


These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1


18 Years - N/A


Female & Male




A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


Trial Dates

Aug 2019 - Oct 2024


None (Open Label)

Enrollment number


A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection as a Single Agent and in Combination with Pembrolizumab in Subjects With Advanced/Metastatic Solid Tumors

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of an Intratumoral Oncolytic Virus in Patients with Advanced Metastatic Solid Tumors? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.


UNC Healthcare

Chapel Hill, United States, 27514

Mary Crowley Cancer Research Center

Dallas, United States, 75251

University of Toledo Medical Center

Toledo, United States, 43614

The Angeles Clinic and Research Institute

Los Angeles, United States, 90025

Nebraska Methodist Hospital

Omaha, United States, 68130

Seattle Cancer Care Alliance

Seattle, United States, 98109

University of Arizona – Arizona Cancer Center

Tucson, United States, 85719

Greenville Health System Cancer Institute

Greenville, United States, 27605

University of Pittsburgh Medical Center

Pittsburgh, United States, 15260

The University of Texas - MD Anderson Cancer Center

Houston, United States, 77030

Henry Ford Hospital

Detroit, United States, 48202

UVA Cancer Center

Charlottesville, United States, 22903

Ochsner Clinic Foundation

New Orleans, United States, 70121

Roswell Park Cancer Institute - Medical Oncology

Buffalo, United States, 14263

University of Maryland Medical Center

Baltimore, United States, 21201

Columbia University Medical Center

New York, United States, 10032

California Cancer Associates for Research & Excellence

Encinitas, United States, 92024

Hartford Healthcare

Hartford, United States, 06106

Norton Cancer Institute

Louisville, United States, 40241

University of Minnesota

Minneapolis, United States, 55455

VCU Massey Cancer Center

Richmond, United States, 23298

Fox Chase Cancer Center

Philadelphia, United States, 19111

University of Alabama at Birmingham

Birmingham, United States, 35233

The University of Chicago Medical Center

Chicago, United States, 60637

University of Kentucky, Markey Cancer Center

Lexington, United States, 40536

Atlantic Health System - Morristown & Overlook Hospital

Morristown, United States, 07960

Karmanos Cancer Institute

Detroit, United States, 48201